Redundancies and Challenges in Biotech: The Case of Off-the-Shelf Cell Therapies

This chapter delves into the challenges faced by biotech companies in the realm of off-the-shelf cell therapies, such as CAR T treatments. The discussion highlights inefficiencies due to overlapping efforts among firms and recent shifts in focus from oncology to autoimmune therapies.